» Articles » PMID: 36457036

MicroRNA-378a-3p Prevents Initiation and Growth of Colorectal Cancer by Fine Tuning Polyamine Synthesis

Overview
Journal Cell Biosci
Publisher Biomed Central
Specialty Biology
Date 2022 Dec 2
PMID 36457036
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Inhibitors of ornithine decarboxylase (ODC) are effective at preventing colorectal cancer (CRC). However, their high toxicity limits their clinical application. This study was aimed to explore the potential of microRNAs (miRNAs) as an inhibitor of ODC.

Methods: miRNA array was used to identify dysregulated miRNAs in CRC tumors of mice and patients. Azoxymethane (AOM)/Dextran Sodium Sulfate (DSS) were used to induce CRC in mice. miRNA function in carcinogenesis was determined by soft-agar colony formation, flow cytometry, and wound healing of CRC cells. Mini-circle was used to deliver miRNA into colons.

Results: MiRNA profiling identified miR-378a-3p (miR-378a) as the most reduced miRNA in CRC tumors of patients and mice treated with AOM/DSS. Pathway array analysis revealed that miR-378a impaired c-MYC and ODC1 pathways. Further studies identified FOXQ1 (forkhead box Q1) and ODC1 as two direct targets of miR-378a. FOXQ1 activated transcription of c-MYC, a transcription activator of ODC1. In addition to directly targeting ODC1, miR-378a also inhibited expression of ODC1 via the FOXQ1-cMYC axis, thereby inhibiting polyamine synthesis in human CRC cells. Phenotypically, by reducing polyamine synthesis, miR-378a induced apoptosis and inhibited proliferation and migration of CRC cells, while disrupting the association of miR-378a with FOXQ1 and ODC1 offset the effects of miR-378a, suggesting that FOXQ1 and ODC1 were required for miR-378a to inhibit CRC cell growth. MiR-378a treatment robustly prevented growth of HCC by inhibiting polyamine synthesis in AOM/DSS mice.

Conclusion: MiR-378a prevents CRC by inhibiting polyamine synthesis, suggesting its use as a novel ODC inhibitor against CRC.

Citing Articles

Crosstalk between non-coding RNAs and programmed cell death in colorectal cancer: implications for targeted therapy.

Taha S, Karimi M, Mahdavi B, Yousefi Tehrani M, Bemani A, Kabirian S Epigenetics Chromatin. 2025; 18(1):3.

PMID: 39810224 PMC: 11734566. DOI: 10.1186/s13072-024-00560-8.


Intestinal -derived small RNAs target porcine polyamine metabolism.

Fan L, Liu B, Wang Y, Tang B, Xu T, Fu J Proc Natl Acad Sci U S A. 2024; 121(41):e2413241121.

PMID: 39361652 PMC: 11474053. DOI: 10.1073/pnas.2413241121.


Unveiling the hidden players: noncoding RNAs orchestrating polyamine metabolism in disease.

Rossi M, Fiorucci C, Mariottini P, Cervelli M Cell Biosci. 2024; 14(1):84.

PMID: 38918813 PMC: 11202255. DOI: 10.1186/s13578-024-01235-3.


Murine models of colorectal cancer: the azoxymethane (AOM)/dextran sulfate sodium (DSS) model of colitis-associated cancer.

Dzhalilova D, Zolotova N, Fokichev N, Makarova O PeerJ. 2023; 11:e16159.

PMID: 37927787 PMC: 10624171. DOI: 10.7717/peerj.16159.

References
1.
Meyer N, Penn L . Reflecting on 25 years with MYC. Nat Rev Cancer. 2008; 8(12):976-90. DOI: 10.1038/nrc2231. View

2.
Coppede F . The role of epigenetics in colorectal cancer. Expert Rev Gastroenterol Hepatol. 2014; 8(8):935-48. DOI: 10.1586/17474124.2014.924397. View

3.
De Robertis M, Massi E, Poeta M, Carotti S, Morini S, Cecchetelli L . The AOM/DSS murine model for the study of colon carcinogenesis: From pathways to diagnosis and therapy studies. J Carcinog. 2011; 10:9. PMC: 3072657. DOI: 10.4103/1477-3163.78279. View

4.
Gerner E, Bruckheimer E, Cohen A . Cancer pharmacoprevention: Targeting polyamine metabolism to manage risk factors for colon cancer. J Biol Chem. 2018; 293(48):18770-18778. PMC: 6290143. DOI: 10.1074/jbc.TM118.003343. View

5.
Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, Klingenhoff A . MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics. 2005; 21(13):2933-42. DOI: 10.1093/bioinformatics/bti473. View